双歧杆菌四联活菌片联合美沙拉嗪肠溶片在溃疡性结肠炎维持治疗中的临床应用效果

Clinical Effect of Bifidobacterium Quadruple Viable Bacteria Tablet Combined with Mesalazine Enteric-Coated Tablet in Maintenance Treatment of Ulcerative Colitis

目的:探讨双歧杆菌四联活菌片联合美沙拉嗪肠溶片在溃疡性结肠炎(UC)维持治疗中的应用效果。方法:前瞻性选取2021年1月至2023年1月收治的68例缓解期UC患者为研究对象,随机分为研究组和对照组,各34例,对照组口服美沙拉嗪肠溶片治疗,研究组在对照组治疗基础上口服双歧杆菌四联活菌片治疗,均连续治疗6个月。比较2组治疗期间复发情况,治疗前后肠镜下黏膜Baron评分、Geboes指数、粪便钙卫蛋白(FC)水平及炎性因子超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-ɑ(TNF-ɑ)、白介素-8(IL-8)水平和生活质量(IBDQ量表),以及治疗期间不良反应发生情况。结果:研究组复发率低于对照组,首次复发时间长于对照组,P<0.05。2组治疗6个月后肠镜下黏膜Baron评分、Geboes指数、FC水平与治疗前相比均明显降低,P<0.05;组间比较,研究组治疗6个月后肠镜下黏膜Baron评分、Geboes指数、FC水平均低于对照组,P<0.05。2组治疗3个月、治疗6个月后hs-CRP、TNF-ɑ、IL-8水平与治疗前相比均明显降低,且治疗6个月后各指标低于治疗3个月后,P<0.05;组间比较,研究组治疗3个月后、治疗6个月后hs-CRP、TNF-ɑ、IL-8水平更低,P<0.05。2组治疗6个月后IBDQ量表各维度得分、总积分与治疗前比较均升高,P<0.05;组间比较,研究组治疗6个月后IBDQ量表各维度得分、总积分均高于对照组,P<0.05。研究组治疗期间不良反应总发生率低于对照组,P<0.05。结论:双歧杆菌四联活菌片联合美沙拉嗪肠溶片用于UC患者维持治疗具有良好效果,可有效缓解肠黏膜状态、减轻炎症反应、减少不良反应、提高患者生活质量。

Objective To investigate the effect of Bifidobacterium Quadruple Viable Bacteria Tablet combined with Mesalazine Enteric-Coated Tablet in the maintenance treatment of ulcerative colitis(UC).Methods A total of 68patients with UC in remission from January 2021to January 2023were prospectively selected as research objects,and randomly divided into the study group and the control group,34cases in each group.The control group was treated with oral Mesalazine Enteric-Coated Tablet,and the study group was treated with oral Bifidobacterium Quadruple Viable Bacteria Tablet on the basis of the control group,for 6consecutive months.The recurrence of the two groups during treatment,mucosal Baron score under colonoscopy,Geboes index,fecal calvetin(FC)level,inflammatory factor levels including hypersensitive C-reactive protein(hs-CRP),tumor necrosis factor-ɑ(TNF-ɑ)and interleukin-8(IL-8),quality of life(IBDQ scale),and the occurrence of adverse reactions during treatment were compared before and after treatment.Results The recurrence rate of the study group was lower than that of the control group,and the first recurrence time was longer than that of the control group(P<0.05).After 6months of treatment,mucosal Baron score under colonoscopy,Geboes index and FC level in both groups were significantly lower than before treatment(P<0.05).After 6months of treatment,mucosal Baron score under colonoscopy,Geboes index and FC level in the study group were lower than those in the control group(P<0.05).The levels of hs-CRP,TNF-ɑand IL-8in both groups after 3months and 6months of treatment were significantly reduced compared with those before treatment,and all indexes after 6months of treatment were lower than those after 3months of treatment(P<0.05).Between groups,the levels of hs-CRP,TNF-ɑand IL-8were lower in the study group after 3months and 6months of treatment(P<0.05).After 6months of treatment,IBDQ scale scores and total scores in both groups were higher than before treatment(P<0.05).After 6months of treatment,IBDQ scores and total scores in the study group were higher than those in the control group(P<0.05).The total incidence of adverse reactions in the study group was lower than that in the control group(P<0.05).Conclusion Bifidobacterium Quadruple Viable Bacteria Tablet combined with Mesalazine Enteric-Coated Tablet has a good effect in maintenance treatment of UC patients,which can effectively alleviate intestinal mucosal status,reduce inflammation,reduce adverse reactions,and improve the quality of life of patients.